Definium Therapeutics (DFTX) Competitors $32.97 +0.87 (+2.71%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest DFTX vs. NBIX, JAZZ, CORT, ELAN, and RDYShould you buy Definium Therapeutics stock or one of its competitors? Definium Therapeutics's main competitors and comparable companies include Neurocrine Biosciences (NBIX), Jazz Pharmaceuticals (JAZZ), Corcept Therapeutics (CORT), Elanco Animal Health (ELAN), and Dr. Reddy's Laboratories (RDY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry. DFTX vs. NBIXDFTX vs. JAZZDFTX vs. CORTDFTX vs. ELANDFTX vs. RDYHow does Definium Therapeutics compare to Neurocrine Biosciences?Definium Therapeutics (NASDAQ:DFTX) and Neurocrine Biosciences (NASDAQ:NBIX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations. Which has better valuation & earnings, DFTX or NBIX? Neurocrine Biosciences has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDefinium TherapeuticsN/AN/A-$183.79M-$3.43N/ANeurocrine Biosciences$2.86B4.82$478.60M$6.8219.90 Does the media refer more to DFTX or NBIX? In the previous week, Neurocrine Biosciences had 17 more articles in the media than Definium Therapeutics. MarketBeat recorded 19 mentions for Neurocrine Biosciences and 2 mentions for Definium Therapeutics. Definium Therapeutics' average media sentiment score of 0.73 beat Neurocrine Biosciences' score of 0.47 indicating that Definium Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neurocrine Biosciences 6 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer DFTX or NBIX? Definium Therapeutics presently has a consensus price target of $66.00, suggesting a potential upside of 105.61%. Neurocrine Biosciences has a consensus price target of $201.14, suggesting a potential upside of 48.21%. Given Definium Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Definium Therapeutics is more favorable than Neurocrine Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Definium Therapeutics 1 Sell rating(s) 0 Hold rating(s) 19 Buy rating(s) 1 Strong Buy rating(s) 2.95Neurocrine Biosciences 0 Sell rating(s) 4 Hold rating(s) 19 Buy rating(s) 1 Strong Buy rating(s) 2.88 Which has more risk & volatility, DFTX or NBIX? Definium Therapeutics has a beta of 2.19, indicating that its share price is 119% more volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market. Do insiders & institutionals hold more shares of DFTX or NBIX? 27.9% of Definium Therapeutics shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 2.4% of Definium Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is DFTX or NBIX more profitable? Neurocrine Biosciences has a net margin of 20.91% compared to Definium Therapeutics' net margin of 0.00%. Neurocrine Biosciences' return on equity of 22.43% beat Definium Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Definium TherapeuticsN/A -84.01% -63.66% Neurocrine Biosciences 20.91%22.43%15.64% SummaryNeurocrine Biosciences beats Definium Therapeutics on 10 of the 14 factors compared between the two stocks.How does Definium Therapeutics compare to Jazz Pharmaceuticals?Definium Therapeutics (NASDAQ:DFTX) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment. Which has preferable valuation & earnings, DFTX or JAZZ? Definium Therapeutics has higher earnings, but lower revenue than Jazz Pharmaceuticals. Definium Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDefinium TherapeuticsN/AN/A-$183.79M-$3.43N/AJazz Pharmaceuticals$4.27B3.20-$356.15M$14.5014.50 Do analysts recommend DFTX or JAZZ? Definium Therapeutics currently has a consensus target price of $66.00, suggesting a potential upside of 105.61%. Jazz Pharmaceuticals has a consensus target price of $291.25, suggesting a potential upside of 38.54%. Given Definium Therapeutics' higher probable upside, equities analysts plainly believe Definium Therapeutics is more favorable than Jazz Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Definium Therapeutics 1 Sell rating(s) 0 Hold rating(s) 19 Buy rating(s) 1 Strong Buy rating(s) 2.95Jazz Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 18 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is DFTX or JAZZ more profitable? Jazz Pharmaceuticals has a net margin of 20.45% compared to Definium Therapeutics' net margin of 0.00%. Jazz Pharmaceuticals' return on equity of 33.97% beat Definium Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Definium TherapeuticsN/A -84.01% -63.66% Jazz Pharmaceuticals 20.45%33.97%13.02% Which has more risk & volatility, DFTX or JAZZ? Definium Therapeutics has a beta of 2.19, meaning that its share price is 119% more volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market. Do insiders and institutionals believe in DFTX or JAZZ? 27.9% of Definium Therapeutics shares are held by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 2.4% of Definium Therapeutics shares are held by company insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media prefer DFTX or JAZZ? In the previous week, Jazz Pharmaceuticals had 6 more articles in the media than Definium Therapeutics. MarketBeat recorded 8 mentions for Jazz Pharmaceuticals and 2 mentions for Definium Therapeutics. Definium Therapeutics' average media sentiment score of 0.73 beat Jazz Pharmaceuticals' score of 0.47 indicating that Definium Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jazz Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryJazz Pharmaceuticals beats Definium Therapeutics on 10 of the 15 factors compared between the two stocks.How does Definium Therapeutics compare to Corcept Therapeutics?Corcept Therapeutics (NASDAQ:CORT) and Definium Therapeutics (NASDAQ:DFTX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation. Is CORT or DFTX more profitable? Corcept Therapeutics has a net margin of 6.52% compared to Definium Therapeutics' net margin of 0.00%. Corcept Therapeutics' return on equity of 8.26% beat Definium Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Corcept Therapeutics6.52% 8.26% 6.45% Definium Therapeutics N/A -84.01%-63.66% Does the media favor CORT or DFTX? In the previous week, Corcept Therapeutics had 9 more articles in the media than Definium Therapeutics. MarketBeat recorded 11 mentions for Corcept Therapeutics and 2 mentions for Definium Therapeutics. Definium Therapeutics' average media sentiment score of 0.73 beat Corcept Therapeutics' score of 0.58 indicating that Definium Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corcept Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Definium Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in CORT or DFTX? 93.6% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 27.9% of Definium Therapeutics shares are owned by institutional investors. 20.7% of Corcept Therapeutics shares are owned by insiders. Comparatively, 2.4% of Definium Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts prefer CORT or DFTX? Corcept Therapeutics currently has a consensus price target of $138.17, indicating a potential upside of 25.42%. Definium Therapeutics has a consensus price target of $66.00, indicating a potential upside of 105.61%. Given Definium Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Definium Therapeutics is more favorable than Corcept Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corcept Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75Definium Therapeutics 1 Sell rating(s) 0 Hold rating(s) 19 Buy rating(s) 1 Strong Buy rating(s) 2.95 Which has more volatility and risk, CORT or DFTX? Corcept Therapeutics has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.19, meaning that its share price is 119% more volatile than the broader market. Which has better earnings & valuation, CORT or DFTX? Corcept Therapeutics has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorcept Therapeutics$761.41M15.64$99.65M$0.42262.29Definium TherapeuticsN/AN/A-$183.79M-$3.43N/A SummaryCorcept Therapeutics beats Definium Therapeutics on 10 of the 15 factors compared between the two stocks.How does Definium Therapeutics compare to Elanco Animal Health?Definium Therapeutics (NASDAQ:DFTX) and Elanco Animal Health (NYSE:ELAN) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership. Do analysts rate DFTX or ELAN? Definium Therapeutics currently has a consensus price target of $66.00, indicating a potential upside of 105.61%. Elanco Animal Health has a consensus price target of $29.91, indicating a potential upside of 26.96%. Given Definium Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Definium Therapeutics is more favorable than Elanco Animal Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Definium Therapeutics 1 Sell rating(s) 0 Hold rating(s) 19 Buy rating(s) 1 Strong Buy rating(s) 2.95Elanco Animal Health 1 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.77 Is DFTX or ELAN more profitable? Definium Therapeutics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -3.96%. Elanco Animal Health's return on equity of 8.13% beat Definium Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Definium TherapeuticsN/A -84.01% -63.66% Elanco Animal Health -3.96%8.13%3.99% Does the media prefer DFTX or ELAN? In the previous week, Elanco Animal Health had 3 more articles in the media than Definium Therapeutics. MarketBeat recorded 5 mentions for Elanco Animal Health and 2 mentions for Definium Therapeutics. Definium Therapeutics' average media sentiment score of 0.73 beat Elanco Animal Health's score of 0.26 indicating that Definium Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger earnings and valuation, DFTX or ELAN? Definium Therapeutics has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDefinium TherapeuticsN/AN/A-$183.79M-$3.43N/AElanco Animal Health$4.72B2.50-$232M-$0.41N/A Which has more risk & volatility, DFTX or ELAN? Definium Therapeutics has a beta of 2.19, indicating that its stock price is 119% more volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.7, indicating that its stock price is 70% more volatile than the broader market. Do insiders & institutionals have more ownership in DFTX or ELAN? 27.9% of Definium Therapeutics shares are owned by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are owned by institutional investors. 2.4% of Definium Therapeutics shares are owned by insiders. Comparatively, 1.1% of Elanco Animal Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryDefinium Therapeutics beats Elanco Animal Health on 9 of the 15 factors compared between the two stocks.How does Definium Therapeutics compare to Dr. Reddy's Laboratories?Definium Therapeutics (NASDAQ:DFTX) and Dr. Reddy's Laboratories (NYSE:RDY) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends. Which has more volatility & risk, DFTX or RDY? Definium Therapeutics has a beta of 2.19, indicating that its share price is 119% more volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market. Does the media prefer DFTX or RDY? In the previous week, Dr. Reddy's Laboratories had 4 more articles in the media than Definium Therapeutics. MarketBeat recorded 6 mentions for Dr. Reddy's Laboratories and 2 mentions for Definium Therapeutics. Definium Therapeutics' average media sentiment score of 0.73 beat Dr. Reddy's Laboratories' score of 0.22 indicating that Definium Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals have more ownership in DFTX or RDY? 27.9% of Definium Therapeutics shares are owned by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 2.4% of Definium Therapeutics shares are owned by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts rate DFTX or RDY? Definium Therapeutics presently has a consensus target price of $66.00, indicating a potential upside of 105.61%. Dr. Reddy's Laboratories has a consensus target price of $732.40, indicating a potential upside of 5,514.41%. Given Dr. Reddy's Laboratories' higher possible upside, analysts plainly believe Dr. Reddy's Laboratories is more favorable than Definium Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Definium Therapeutics 1 Sell rating(s) 0 Hold rating(s) 19 Buy rating(s) 1 Strong Buy rating(s) 2.95Dr. Reddy's Laboratories 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Which has better valuation and earnings, DFTX or RDY? Dr. Reddy's Laboratories has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDefinium TherapeuticsN/AN/A-$183.79M-$3.43N/ADr. Reddy's Laboratories$3.58B3.04$456M$0.4429.65 Is DFTX or RDY more profitable? Dr. Reddy's Laboratories has a net margin of 10.15% compared to Definium Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 9.49% beat Definium Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Definium TherapeuticsN/A -84.01% -63.66% Dr. Reddy's Laboratories 10.15%9.49%6.32% SummaryDr. Reddy's Laboratories beats Definium Therapeutics on 9 of the 16 factors compared between the two stocks. Get Definium Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DFTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DFTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DFTX vs. The Competition ExportMetricDefinium TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ ExchangeMarket Cap$4.43B$12.57B$7.38B$12.77BDividend YieldN/A2.60%2.50%27.65%P/E Ratio-9.61800.14274.5224.98Price / SalesN/A930.40638.6699.79Price / CashN/A15.1826.7233.56Price / Book9.819.2610.515.91Net Income-$183.79M$2.83B$3.50B$380.83M7 Day Performance-6.34%-4.52%-4.14%-4.31%1 Month Performance-15.05%-9.13%-9.05%-8.25%1 Year Performance141.54%-5.80%1.85%-5.22% Definium Therapeutics Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DFTXDefinium Therapeutics3.612 of 5 stars$32.97+2.7%$66.00+100.2%+135.2%$4.43BN/AN/A40Positive NewsAnalyst ForecastNBIXNeurocrine Biosciences4.8686 of 5 stars$141.37-0.8%$201.14+42.3%-3.1%$14.48B$3.37B20.732,000Analyst ForecastJAZZJazz Pharmaceuticals4.3881 of 5 stars$216.75-0.8%$291.25+34.4%+54.5%$14.18B$4.60B14.952,890CORTCorcept Therapeutics4.6605 of 5 stars$121.19flat$138.17+14.0%+40.0%$13.10B$761.41M288.55730News CoverageInsider TradeELANElanco Animal Health3.9928 of 5 stars$22.58-1.5%$29.70+31.6%+10.0%$11.45B$4.72BN/A9,400Analyst ForecastInsider Trade Related Companies and Tools Related Companies NBIX Alternatives JAZZ Alternatives CORT Alternatives ELAN Alternatives RDY Alternatives AXSM Alternatives LNTH Alternatives AMRX Alternatives BLTE Alternatives MANE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DFTX) was last updated on 10/19/2026 by MarketBeat.com Staff. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Definium Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Definium Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
